Assessing hERG Pore Models As Templates for Drug Docking Using Published Experimental Constraints: The Inactivated State in the Context of Drug Block

Many structurally and therapeutically diverse drugs interact with the human heart K+ channel hERG by binding within the K+ permeation pathway of the open channel, leading to drug-induced ‘long QT syndrome’. Drug binding to hERG is often stabilized by inactivation gating. In the absence of a crystal structure, hERG pore homology models have been used to characterize drug interactions. Here we assess potentially inactivated states of the bacterial K+ channel, KcsA, as templates for inactivated state hERG pore models in the context of drug binding using computational docking. Although Flexidock and GOLD docking produced low energy score poses in the models tested, each method selected a MthK K+ channel-based model over models based on the putative inactivated state KcsA structures for each of the 9 drugs tested. The variety of docking poses found indicates that an optimal arrangement for drug binding of aromatic side chains in the hERG pore can be achieved in several different configurations. This plasticity of the drug “binding site” is likely to be a feature of the hERG inactivated state. The results demonstrate that experimental data on specific drug interactions can be used as structural constraints to assess and refine hERG homology models.

[1]  Nicole Schmitt,et al.  Local Anesthetic Interaction with Human Ether-a-go-go–related Gene (HERG) Channels: Role of Aromatic Amino Acids Y652 and F656 , 2005, Anesthesiology.

[2]  M. Cadene,et al.  X-ray structure of a voltage-dependent K+ channel , 2003, Nature.

[3]  Liang Guo,et al.  Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation. , 2005, Journal of pharmacological and toxicological methods.

[4]  U. Zachariae,et al.  Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers. , 2009, Journal of medicinal chemistry.

[5]  Michael C Sanguinetti,et al.  Predicting drug-hERG channel interactions that cause acquired long QT syndrome. , 2005, Trends in pharmacological sciences.

[6]  Gert Vriend,et al.  Toward a Consensus Model of the hERG Potassium Channel , 2010, ChemMedChem.

[7]  P. Focia,et al.  Structural basis of TEA blockade in a model potassium channel , 2005, Nature Structural &Molecular Biology.

[8]  Pavel Jungwirth,et al.  Specificity of ion-protein interactions: complementary and competitive effects of tetrapropylammonium, guanidinium, sulfate, and chloride ions. , 2009, The journal of physical chemistry. B.

[9]  S. Heinemann,et al.  Molecular determinants for activation and inactivation of HERG, a human inward rectifier potassium channel. , 1996, The Journal of physiology.

[10]  Haruo Honjo,et al.  Molecular determinants of hERG channel block by terfenadine and cisapride. , 2008, Journal of pharmacological sciences.

[11]  Yumi N Imai,et al.  Docking model of drug binding to the human ether-à-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach. , 2009, Journal of medicinal chemistry.

[12]  Jules C. Hancox,et al.  Interactions between Voltage Sensor and Pore Domains in a hERG K+ Channel Model from Molecular Simulations and the Effects of a Voltage Sensor Mutation , 2013, J. Chem. Inf. Model..

[13]  Eduardo Perozo,et al.  Structural mechanism of C-type inactivation in K+ channels , 2010, Nature.

[14]  M. Jiang,et al.  Differential Effects of Bupivacaine on Cardiac K Channels: Role of Channel Inactivation and Subunit Composition in Drug—Channel Interaction , 1998, Journal of cardiovascular electrophysiology.

[15]  Yi H. Zhang,et al.  Molecular determinants of hERG potassium channel inhibition by disopyramide. , 2012, Journal of molecular and cellular cardiology.

[16]  Stefan A. Mann,et al.  hERG K(+) channels: structure, function, and clinical significance. , 2012, Physiological reviews.

[17]  Jyoti Chattopadhyaya,et al.  Computational and NMR study of quaternary ammonium ion conformations in solution , 2002 .

[18]  A. Brown,et al.  Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. , 2004, Journal of pharmacological and toxicological methods.

[19]  J. Mitcheson,et al.  Molecular determinants of high-affinity drug binding to HERG channels. , 2003, Current opinion in drug discovery & development.

[20]  M. Sanguinetti,et al.  Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Antoine Daina,et al.  Block of the hERG channel by bupivacaine: Electrophysiological and modeling insights towards stereochemical optimization. , 2011, European journal of medicinal chemistry.

[22]  R. Rosenfeld Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[23]  P. Tarantino,et al.  Effect of trazodone on hERG channel current and QT-interval. , 2005, European journal of pharmacology.

[24]  M. Sanguinetti,et al.  A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Jun Chen,et al.  A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Johannes Brussee,et al.  Exploring Chemical Substructures Essential for hERG K+ Channel Blockade by Synthesis and Biological Evaluation of Dofetilide Analogues , 2009, ChemMedChem.

[27]  Yang Li,et al.  Novel insights into K+ selectivity from high resolution structures of an open K+ channel pore , 2010, Nature Structural &Molecular Biology.

[28]  Elizabeth Yuriev,et al.  Latest developments in molecular docking: 2010–2011 in review , 2013, Journal of molecular recognition : JMR.

[29]  Henggui Zhang,et al.  Action potential clamp and chloroquine sensitivity of mutant Kir2.1 channels responsible for variant 3 short QT syndrome , 2009, Journal of molecular and cellular cardiology.

[30]  Serdar Durdagi,et al.  Modeling of Open, Closed, and Open-Inactivated States of the hERG1 Channel: Structural Mechanisms of the State-Dependent Drug Binding , 2012, J. Chem. Inf. Model..

[31]  Adriaan P IJzerman,et al.  Understanding of Molecular Substructures that Contribute to hERG K+ Channel Blockade: Synthesis and Biological Evaluation of E‐4031 Analogues , 2012, ChemMedChem.

[32]  Ingo Muegge,et al.  Docking and Scoring , 2003 .

[33]  Lu Chen,et al.  A Critical Assessment of Combined Ligand- and Structure-Based Approaches to hERG Channel Blocker Modeling , 2011, J. Chem. Inf. Model..

[34]  Youxing Jiang,et al.  Crystal structure and mechanism of a calcium-gated potassium channel , 2002, Nature.

[35]  Kaichiro Kamiya,et al.  Molecular Determinants of hERG Channel Block , 2006, Molecular Pharmacology.

[36]  Peter Wolschann,et al.  In silico Analysis of Conformational Changes Induced by Mutation of Aromatic Binding Residues: Consequences for Drug Binding in the hERG K+ Channel , 2011, PloS one.

[37]  William L. Jorgensen,et al.  Journal of Chemical Information and Modeling , 2005, J. Chem. Inf. Model..

[38]  M. Sutcliffe,et al.  Drug block of the hERG potassium channel: Insight from modeling , 2007, Proteins.

[39]  M. Sanguinetti,et al.  hERG potassium channels and cardiac arrhythmia , 2006, Nature.

[40]  Geoffrey Chang,et al.  Understanding polyspecificity of multidrug ABC transporters: closing in on the gaps in ABCB1. , 2010, Trends in biochemical sciences.

[41]  Martin Traebert,et al.  Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells. , 2004, European journal of pharmacology.

[42]  J. Richardson,et al.  The penultimate rotamer library , 2000, Proteins.

[43]  Michael C Sanguinetti,et al.  Structural Determinants of HERG Channel Block by Clofilium and Ibutilide , 2004, Molecular Pharmacology.

[44]  F. Österberg,et al.  Exploring blocker binding to a homology model of the open hERG K+ channel using docking and molecular dynamics methods , 2005, FEBS letters.

[45]  Michael C Sanguinetti,et al.  Molecular Determinants of Voltage-dependent Human Ether-a-Go-Go Related Gene (HERG) K+ Channel Block* , 2002, The Journal of Biological Chemistry.

[46]  Robin Taylor,et al.  Comparing protein–ligand docking programs is difficult , 2005, Proteins.

[47]  D. E. Clark,et al.  Flexible docking using tabu search and an empirical estimate of binding affinity , 1998, Proteins.

[48]  C. E. Peishoff,et al.  A critical assessment of docking programs and scoring functions. , 2006, Journal of medicinal chemistry.

[49]  Benoît Roux,et al.  Mechanism of intracellular block of the KcsA K+ channel by tetrabutylammonium: insights from X-ray crystallography, electrophysiology and replica-exchange molecular dynamics simulations. , 2007, Journal of molecular biology.

[50]  Jules C Hancox,et al.  The Low-Potency, Voltage-Dependent HERG Blocker Propafenone—Molecular Determinants and Drug Trapping , 2004, Molecular Pharmacology.

[51]  Stanley Nattel,et al.  Dofetilide block involves interactions with open and inactivated states of HERG channels , 2002, Pflügers Archiv - European Journal of Physiology.

[52]  C. January,et al.  Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. , 1998, Biophysical journal.

[53]  Thomas Stützle,et al.  Empirical Scoring Functions for Advanced Protein-Ligand Docking with PLANTS , 2009, J. Chem. Inf. Model..

[54]  R. Cramer,et al.  Validation of the general purpose tripos 5.2 force field , 1989 .

[55]  Jamie I Vandenberg,et al.  Drug Binding to the Inactivated State Is Necessary but Not Sufficient for High-Affinity Binding to Human Ether-à-go-go-Related Gene Channels , 2008, Molecular Pharmacology.

[56]  Christopher E. Dempsey,et al.  Complex ion effects on polypeptide conformational stability: chloride and sulfate salts of guanidinium and tetrapropylammonium. , 2011, Journal of the American Chemical Society.

[57]  H. Duff,et al.  Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. , 2000, Molecular pharmacology.

[58]  A. Cavalli,et al.  Computational design and discovery of "minimally structured" hERG blockers. , 2012, Journal of medicinal chemistry.

[59]  A. Brown,et al.  Molecular determinants of dofetilide block of HERG K+ channels. , 1998, Circulation research.

[60]  B Attali,et al.  The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes , 1997, British journal of pharmacology.

[61]  Adriaan P IJzerman,et al.  Strategies to reduce HERG K+ channel blockade. Exploring heteroaromaticity and rigidity in novel pyridine analogues of dofetilide. , 2013, Journal of medicinal chemistry.

[62]  B. Chait,et al.  The structure of the potassium channel: molecular basis of K+ conduction and selectivity. , 1998, Science.

[63]  R. Friesner,et al.  New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies. , 2006, Bioorganic & medicinal chemistry.

[64]  J. Hancox,et al.  Pharmacology of the short QT syndrome N588K‐hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs , 2008, British journal of pharmacology.

[65]  Michael J Sutcliffe,et al.  Drug Binding Interactions in the Inner Cavity of hERG Channels: Molecular Insights from Structure-Activity Relationships of Clofilium and Ibutilide Analogs , 2006, Molecular Pharmacology.

[66]  Brian K Shoichet,et al.  Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. , 2006, Journal of medicinal chemistry.

[67]  Jules C Hancox,et al.  The hERG potassium channel and hERG screening for drug-induced torsades de pointes. , 2008, Pharmacology & therapeutics.